Mechanical circulatory support, particularly PCPS and ECMO, has expanded the range of treatable conditions and improved survival rates for patients with severe heart failure.
This 2023 focused update provides guidelines on the indications and management of mechanical circulatory support devices (PCPS, ECMO, IMPELLA) for severe heart failure.
Mechanical circulatory support (MCS) plays a significant role as a therapeutic option for severe heart failure, and its outcomes have been improving due to advancements in devices and management techniques. In particular, percutaneous cardiopulmonary support (PCPS) and extracorporeal membrane oxygenation (ECMO) have contributed to both expanding the range of conditions that can be treated and improving survival rates through the accumulation of knowledge on the clinical introduction, indications, and management of these novel devices in recent years.
Nishimura et al. (Fri,) conducted a review in Severe heart failure. Mechanical circulatory support (PCPS/ECMO/IMPELLA) was evaluated. Mechanical circulatory support, particularly PCPS and ECMO, has expanded the range of treatable conditions and improved survival rates for patients with severe heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: